Dana Investment Advisors Inc. Sells 54,542 Shares of Bristol Myers Squibb Company $BMY

Dana Investment Advisors Inc. lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 37.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 90,612 shares of the biopharmaceutical company’s stock after selling 54,542 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Bristol Myers Squibb were worth $4,087,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. raised its position in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. bought a new stake in Bristol Myers Squibb during the second quarter worth $38,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $40,000. Finally, Mark Sheptoff Financial Planning LLC boosted its holdings in shares of Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 700 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA accepted the NDA for iberdomide in relapsed/refractory multiple myeloma and granted Priority Review and Breakthrough Therapy designation — a fast regulatory path that could add a new oral therapy to BMY’s oncology franchise and materially boost future revenue if approved. FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review
• Positive Sentiment: Positive top-line registrational Phase 2 results for luspatercept in adults with alpha‑thalassemia — successful data supports a potential label expansion (new indication) and adds to the company’s near-term pipeline value. Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $75 price target, highlighting pipeline potential and supporting higher analyst sentiment and buy-side interest. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential
• Neutral Sentiment: Market commentary and valuation pieces are re‑rating BMY as investors digest the clinical/regulatory wins — these articles analyze upside and valuation multiples but don’t add immediate cash-flow changes. Assessing Bristol Myers Squibb (BMY) Valuation After Key Multiple Myeloma And Alpha Thalassemia Updates
• Neutral Sentiment: BMY will present at the TD Cowen Health Care Conference — an opportunity for management to update investors on pipeline timelines and commercial plans; typically a catalyst for guidance clarity but not an immediate earnings event. Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
• Negative Sentiment: Analysts and coverage notes continue to flag a looming patent/exclusivity cliff for some key products — a structural risk that could pressure revenue beyond the near-term pipeline gains. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential

Bristol Myers Squibb Stock Up 0.6%

Shares of NYSE BMY opened at $61.61 on Wednesday. The company has a 50 day simple moving average of $56.50 and a 200 day simple moving average of $50.26. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The firm has a market cap of $125.48 billion, a PE ratio of 17.86, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BMY shares. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Morgan Stanley reissued an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Leerink Partners upped their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday. They issued a “sector perform” rating and a $60.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $60.71.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.